CN1061232C - A Chinese medicinal composition for treating gastritis and ulcer - Google Patents
A Chinese medicinal composition for treating gastritis and ulcer Download PDFInfo
- Publication number
- CN1061232C CN1061232C CN96117527A CN96117527A CN1061232C CN 1061232 C CN1061232 C CN 1061232C CN 96117527 A CN96117527 A CN 96117527A CN 96117527 A CN96117527 A CN 96117527A CN 1061232 C CN1061232 C CN 1061232C
- Authority
- CN
- China
- Prior art keywords
- ulcer
- chinese medicinal
- medicinal composition
- furazolidone
- metoclopramide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 7
- 208000025865 Ulcer Diseases 0.000 title abstract description 4
- 231100000397 ulcer Toxicity 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 title description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960004503 metoclopramide Drugs 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 claims description 8
- 229960001625 furazolidone Drugs 0.000 claims description 8
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 201000005917 gastric ulcer Diseases 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 208000012895 Gastric disease Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 208000018556 stomach disease Diseases 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 2
- 229940083568 furazolidone 100 mg Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940048924 metoclopramide 10 mg Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating gastritis and ulcer, which comprises an antibacterial agent, sodium carbonate, metoclopramide and the like.
Description
The present invention relates to the treatment gastritis, gastric ulcer, the duodenal ulcer medicine that are combined into by antibacterial furazolidone and sodium bicarbonate, metoclopramide.
People are known, and furazolidone has certain deep and remote spirillum effect of stomach of killing, and need take medicine for a long time but treat above-mentioned gastropathy (hereinafter to be referred as gastropathy), and two weeks is above and the effect of paying is bigger at least.Be difficult for curing gastropathy.
The present inventor finds: be equipped with alkaline matter in antibacterial, changing the affected part sour environment is alkalescence, and the effect of antibacterial obviously strengthens.
The object of the present invention is achieved like this, and this pharmaceutical composition contains sodium bicarbonate, furazolidone, metoclopramide, and the component proportioning of the quality of its furazolidone, sodium bicarbonate, metoclopramide is 10: (50-150): (0.5～1); Furazolidone can be by other antibiotic neat replacement, as gentamycin, metronidazole, erythromycin, sulfanilamide, penicillin series medicine etc.; Metoclopramide can also add other adjuvant with the many ketone replacement of Pan.
Further specify the present invention below by embodiment.
Embodiment 1: furazolidone 100mg, sodium bicarbonate 1g metoclopramide 10mg.
Embodiment 2: gentamycin 800,000, calcium lactate 1g, many ketone of Pan 10mg.
Embodiment 3: furazolidone 100mg, calcium lactate 1g, many ketone of Pan 10mg.
The purpose of this invention is to provide a kind of pharmaceutical composition of controlling gastritis, gastric ulcer, this pharmaceutical composition has cure rate height, characteristics such as short treating period.Mix sodium bicarbonate with furazolidone, the patient only need take medicine 2-3 day, and patient's cardinal symptom is removed rapidly, and does not need to take medicine again, and patient promptly fully recovers.The present inventor has treated 141 examples, and none is ineffective, and does not have 1 example recurrence, healing person's also not recurrence of in March, 5 even to this day at first.
Antibacterial of the present invention comprises: gentamycin, metronidazole, erythromycin, sulfanilamide, penicillin series medicine.
Medicine sodium bicarbonate of the present invention also can be with replacement such as calcium lactate, but is not limited only to this.
The adjuvant metoclopramide that the present invention allocates into can also can add other adjuvant with the many ketone replacement of Pan.
Said preparation is controlled gastropathy clinical practice 141 examples, and be 3 medicine time, and every day three times, dosage is furazolidone 0.1g, and the hydrogen of carbon is received 1g, metoclopramide 10mg.The back patient that takes medicine all cures, follow up a case by regular visits to the longest 5 years after 141 examples are cured, in the shortest week, find that all recurrence sees Table: disease duodenum and the duodenal bulbar ulcer gastric ulcer gastritis number 7 22 112 healing numbers 7 22 112 recurrence numbers 000 of taking medicine
Above case all is after hospital makes a definite diagnosis, and it is not obvious to take other drug effect fruit repeatedly, changes clothes present composition patient again.
Claims (1)
1, a kind of treatment gastritis, gastric ulcer pharmaceutical composition is characterized in that containing sodium bicarbonate, furazolidone, metoclopramide, and mass ratio is 1000: 100: 10 (mg).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96117527A CN1061232C (en) | 1996-04-12 | 1996-04-12 | A Chinese medicinal composition for treating gastritis and ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96117527A CN1061232C (en) | 1996-04-12 | 1996-04-12 | A Chinese medicinal composition for treating gastritis and ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1162449A CN1162449A (en) | 1997-10-22 |
| CN1061232C true CN1061232C (en) | 2001-01-31 |
Family
ID=5124371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96117527A Expired - Fee Related CN1061232C (en) | 1996-04-12 | 1996-04-12 | A Chinese medicinal composition for treating gastritis and ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1061232C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081614A (en) * | 1992-04-24 | 1994-02-09 | 阿斯特拉公司 | Have the secretory material of gastric acid inhibitory with can be by the antibiotic cooperative compositions of acid degradation |
| CN1087000A (en) * | 1993-07-05 | 1994-05-25 | 大庆欧达医药临床应用开发研究所 | A kind of compound recipe stomach medicine that cures mainly Peptic Ulcers |
-
1996
- 1996-04-12 CN CN96117527A patent/CN1061232C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081614A (en) * | 1992-04-24 | 1994-02-09 | 阿斯特拉公司 | Have the secretory material of gastric acid inhibitory with can be by the antibiotic cooperative compositions of acid degradation |
| CN1087000A (en) * | 1993-07-05 | 1994-05-25 | 大庆欧达医药临床应用开发研究所 | A kind of compound recipe stomach medicine that cures mainly Peptic Ulcers |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1162449A (en) | 1997-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004002445A3 (en) | Novel floating dosage form | |
| DE2105925C3 (en) | Medicines with a calcium level-raising and recalcification-promoting effect | |
| CN1061232C (en) | A Chinese medicinal composition for treating gastritis and ulcer | |
| Brunner et al. | The potential clinical role of intravenous omeprazole | |
| CN101837019A (en) | American cockroach medicinal composition for curing oral ulcers and preparation method thereof | |
| SE9001308D0 (en) | PROCEDURAL PROCEDURES FOR TREATING AND PREVENTING OBJECTIVE | |
| Butler et al. | Intravenous histamine in the treatment of migraine: Preliminary observations | |
| US5128141A (en) | Association of physiologically dosed vitamin a and of various active principles having a therapeutical activity | |
| CN1052403C (en) | Quick effect active ion calcium | |
| CN101199553B (en) | Preparing method for treating diabetes whole silkworm powder | |
| CN205672254U (en) | A kind of pill treating chicken coccidiosis | |
| SU724141A1 (en) | Agent for treating trophic ulcers | |
| CN1088378C (en) | Oral Chinese medicine liquid for treating chronic superficial gastritis and its preparation | |
| SU1105202A1 (en) | Method of treatment of gastric ulcer and duodenal ulcer | |
| CN112569225B (en) | Non-drug helicobacter pylori bactericidal composition | |
| RU93037431A (en) | ENTERSORBENT FOR THE REMOVAL OF RADIONUCLIDES DEPOSITED IN THE ORGANISM | |
| CN1051455C (en) | Liquid medicine for curing burn or scald and preparation method thereof | |
| SU692604A1 (en) | Preparation for treating salmonollosis, collibacillosis, gastroenterocolitis of microbe etiology | |
| SU1309968A1 (en) | Method of treatment of pancreatonecrosis | |
| CN1122525C (en) | Medicine for treating gastropathy and preparation process thereof | |
| CN111671083A (en) | Method for promoting metabolism of human body and exciting self-repairing capability of organism | |
| CN1163144A (en) | Chinese drug liquid for curing chilblain and scabies | |
| RU2351341C2 (en) | Method of treating chronic duodenal obstruction | |
| CN1106278A (en) | Ulcer powder | |
| CN1156607A (en) | Shuangwujiangtang capsule for reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |